Market/Novel Tech Articles
Novartis announces that FDA brolucizumab injection approves to be noninferior to aflibercept in Phase III studies
Novartis AG (NYSE:NVS; SIX:NOVN) has announced that the U.S. Food and Drug Administration (FDA) has approved brolucizumab (“Beovu”) injection (also known as RTH258) for the treatment of wet age-related macular degeneration (AMD). According to the company, the product is the first FDA approved anti-VEGF to offer both greater fluid resolution versus aflibercept “and the ability […]Read full story
A UK gene therapy company – Gyroscope Therapeutics Ltd – raises £50.4 million funding for retinal disease treatment
Gyroscope Therapeutics Ltd., based in Stevenage, UK, has announced the successful completion of a £50.4 million investment to advance clinical development of an investigational gene therapy treatment for dry age-related macular degeneration (dry-AMD). The company is built on studies and scientific publications which link chronic local inflammation, activation of the complement system and AMD pathogenesis […]Read full story
UK researchers highlight negative consequences of Brexit for the development of and access to medicines for orphan (rare) diseases in paediatrics.
UK researchers in Queens University Belfast (QUB) have published an article on the implications of a “no deal” Brexit for orphan and paediatric medicines. The research, published in the British Medical Journal (BMJ), stressed that the impending exit of the UK from the EU “would have considerable adverse consequences on pharmaceutical research and development and […]Read full story